163 related articles for article (PubMed ID: 7516262)
1. The New American Joint Committee on Cancer and International Union Against Cancer TNM classification of prostate cancer. Clinicopathologic correlations.
Ohori M; Wheeler TM; Scardino PT
Cancer; 1994 Jul; 74(1):104-14. PubMed ID: 7516262
[TBL] [Abstract][Full Text] [Related]
2. [The 1992 TNM classification of T2 prostate cancer predicts pathologic stage and prognosis better than the revised 1997 classification].
Koh H; Maru N; Muramoto M; Wheeler TM; Scardino PT; Ohori M
Nihon Hinyokika Gakkai Zasshi; 2002 Jul; 93(5):595-601. PubMed ID: 12174634
[TBL] [Abstract][Full Text] [Related]
3. Improved clinical staging system combining biopsy laterality and TNM stage for men with T1c and T2 prostate cancer: results from the SEARCH database.
Freedland SJ; Presti JC; Terris MK; Kane CJ; Aronson WJ; Dorey F; Amling CL;
J Urol; 2003 Jun; 169(6):2129-35. PubMed ID: 12771734
[TBL] [Abstract][Full Text] [Related]
4. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer.
Epstein JI; Walsh PC; Carmichael M; Brendler CB
JAMA; 1994 Feb; 271(5):368-74. PubMed ID: 7506797
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of visible lesions on transrectal ultrasound in impalpable prostate cancers: implications for staging.
Augustin H; Graefen M; Palisaar J; Blonski J; Erbersdobler A; Daghofer F; Huland H; Hammerer PG
J Clin Oncol; 2003 Aug; 21(15):2860-8. PubMed ID: 12885802
[TBL] [Abstract][Full Text] [Related]
6. Are prostate carcinoma clinical stages T1c and T2 similar?
Billis A; Magna LA; Watanabe IC; Costa MV; Telles GH; Ferreira U
Int Braz J Urol; 2006; 32(2):165-71. PubMed ID: 16650293
[TBL] [Abstract][Full Text] [Related]
7. The T classification of clinically localized prostate cancer. An appraisal based on disease outcome after radiation therapy.
Zagars GK; Geara FB; Pollack A; von Eschenbach AC
Cancer; 1994 Apr; 73(7):1904-12. PubMed ID: 7511040
[TBL] [Abstract][Full Text] [Related]
8. Comparison of clinically nonpalpable prostate-specific antigen-detected (cT1c) versus palpable (cT2) prostate cancers in patients undergoing radical retropubic prostatectomy.
Ghavamian R; Blute ML; Bergstralh EJ; Slezak J; Zincke H
Urology; 1999 Jul; 54(1):105-10. PubMed ID: 10414735
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of prostate-specific antigen in stage T1c prostate cancer treated by radical prostatectomy.
Cookson MS; Fleshner NE; Soloway SM; Fair WR
Urology; 1997 Jun; 49(6):887-93. PubMed ID: 9187696
[TBL] [Abstract][Full Text] [Related]
10. Pathological characteristics and prognosis of nonpalpable and palpable prostate cancers with a Hybritech prostate specific antigen of 4 to 10 ng./ml.
Geary ES; Stamey TA
J Urol; 1996 Sep; 156(3):1056-8. PubMed ID: 8709306
[TBL] [Abstract][Full Text] [Related]
11. Has there been a recent shift in the pathological features and prognosis of patients treated with radical prostatectomy?
Soh S; Kattan MW; Berkman S; Wheeler TM; Scardino PT
J Urol; 1997 Jun; 157(6):2212-8. PubMed ID: 9146618
[TBL] [Abstract][Full Text] [Related]
12. Clinical and pathological characteristics, and recurrence rates of stage T1c versus T2a or T2b prostate cancer.
Ramos CG; Carvalhal GF; Smith DS; Mager DE; Catalona WJ
J Urol; 1999 May; 161(5):1525-9. PubMed ID: 10210388
[TBL] [Abstract][Full Text] [Related]
13. Comparison of T1c versus T2 prostate cancers in Japanese patients undergoing radical prostatectomy.
Furuya Y; Ohta S; Sato N; Kotake T; Masai M
Int Urol Nephrol; 2002; 33(1):73-6. PubMed ID: 12090344
[TBL] [Abstract][Full Text] [Related]
14. Clinical Stage B0 or T1c prostate cancer: nonpalpable disease identified by elevated serum prostate-specific antigen concentration.
Stormont TJ; Farrow GM; Myers RP; Blute ML; Zincke H; Wilson TM; Oesterling JE
Urology; 1993 Jan; 41(1):3-8. PubMed ID: 7678359
[TBL] [Abstract][Full Text] [Related]
15. Staging prostate cancer--1997: current methods and limitations.
Bostwick DG
Eur Urol; 1997; 32 Suppl 3():2-14. PubMed ID: 9267781
[TBL] [Abstract][Full Text] [Related]
16. Transrectal ultrasound-guided transperineal 14-core systematic biopsy detects apico-anterior cancer foci of T1c prostate cancer.
Kawakami S; Kihara K; Fujii Y; Masuda H; Kobayashi T; Kageyama Y
Int J Urol; 2004 Aug; 11(8):613-8. PubMed ID: 15285751
[TBL] [Abstract][Full Text] [Related]
17. Comparison of pathologic characteristics of T1c and non-T1c cancers detected in a population-based screening study, the European Randomized Study of Screening for Prostate Cancer.
Hoedemaeker RF; Rietbergen JB; Kranse R; van der Kwast TH; Schröder FH
World J Urol; 1997; 15(6):339-45. PubMed ID: 9436283
[TBL] [Abstract][Full Text] [Related]
18. Characteristics of prostate cancers detected in a multimodality early detection program. The Investigators of the American Cancer Society-National Prostate Cancer Detection Project.
Mettlin C; Murphy GP; Lee F; Littrup PJ; Chesley A; Babaian R; Badalament R; Kane RA; Mostofi FK
Cancer; 1993 Sep; 72(5):1701-8. PubMed ID: 7688658
[TBL] [Abstract][Full Text] [Related]
19. Patients with abnormal ultrasound of the prostate but normal digital rectal examination should be classified as having clinical stage T2 tumors.
Tiguert R; Gheiler EL; Grignon DJ; Littrup PJ; Sakr W; Pontes JE; Wood DP
J Urol; 2000 May; 163(5):1486-90. PubMed ID: 10751863
[TBL] [Abstract][Full Text] [Related]
20. Do impalpable stage T1c prostate cancers visible on ultrasound differ from those not visible?
Ohori M; Kattan MW; Utsunomiya T; Suyama K; Scardino PT; Wheeler TM
J Urol; 2003 Mar; 169(3):964-8. PubMed ID: 12576823
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]